Innovative technologies to effectively treat Multi-drug resistant and/or biofilm-

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$172,763.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43GM093398-01A1
Award Id:
96204
Agency Tracking Number:
GM093398
Solicitation Year:
n/a
Solicitation Topic Code:
NIGMS
Solicitation Number:
n/a
Small Business Information
INNOVATIVE SURFACE TECHNOLOGIES, INC., 1000 WESTGATE DR, STE 115, ST. PAUL, MN, 55114
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
148070860
Principal Investigator:
JIEWEN
(651) 209-9757
JWEN@ISURTEC.COM
Business Contact:
PATRICKGUIRE
() -
wvandervort@isurtec.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): This Phase I project is to evaluate a series of novel drug combinations to prevent and treat wound infections. Wounds have certain characteristics that promote the development of infections: the presence of devitalized tissue, foreign bodies, clots, fluid collections, and contamination of wounds with bacteria from the casualty's skin, the environment and the hospital. Medical reports from the military actions in Iraq and Afghanistan confirmed the emergence of multi-drug resistant bacteria (MDR) such as Acinetobacter baumannii, Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus, and multi-drug resistant Pseudomonas aeruginosa. Infections caused by these multi-drug resistant organisms appear to result in sig nificant morbidity and mortality. Bacteria within biofilms are inherently insensitive to antiseptics, microbicides, and host immune system. To complicate the problem further, the MDR bacteria can form biofilm at the wound sites or implant surfaces, causing infections that are insensitive to host immune system and antibiotic therapies. An effective antimicrobial strategy to prevent and treat biofilm is desperately needed in both military and civilian care. In this project, we propose a series of novel drug c ombinations as antibiofilm formulations. Efficacy of the antibiofilm formulations will be assessed in a wound dressing model using nanofibrillar chitosan meshes as a topical delivery carrier. The proposed technology combines characteristics including nanof ibrillar barrier, hemostatic activity, antibiofilm efficacy, and controlled release strategy. PUBLIC HEALTH RELEVANCE: It was estimated that nosocomial infections affect about 2.0 M people in the U.S. each year and costs more than 11.0 B to the hea lthcare providers. Wound care and indwelling catheters, the two most commonly associated areas of infection, experienced a surge of antimicrobial devices in the 1990s. By 2007, the US wound care market has grown to an estimated 10 B. This growth has drive n efforts to reduce infection that resulted in the development of antimicrobial dressings.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government